|Bid||16.13 x 1000|
|Ask||18.75 x 1800|
|Day's Range||16.10 - 16.33|
|52 Week Range||15.92 - 34.99|
|Beta (5Y Monthly)||0.73|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.55|
PLANEGG, GERMANY and MUNICH, GERMANY / ACCESSWIRE / July 21, 2021 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR), a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST (4:00pm EDT).MorphoSys' Management Board will host a conference call and webcast on July 29, 2021 at 2:00pm CEST (8:00am EDT) to present the second quarter and first half financial results 2021 and p
The new ordinary shares represent 3.9% of the registered share capital of MorphoSys following the capital increase.
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty PharmaPLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. (NASDAQ:CNST) ("Constellation") for $34.